scholarly journals Comparison of rates of hospitalization between single and dual virus detection in a Mexican cohort of children and adults with influenza-like illness

Author(s):  
Daniel E Noyola ◽  
Sally Hunsberger ◽  
Raydel Valdés Salgado ◽  
John H Powers ◽  
Arturo Galindo-Fraga ◽  
...  

Abstract Background Molecular detection methods allow for the simultaneous detection of several infectious agents. This study assesses whether co-infection with two viruses as compared to one is associated with increased hospitalization in those with acute respiratory infections. Methods We prospectively enrolled a cohort of pediatric and adult participants with influenza-like illness during 2010-2014 in Mexico. Clinical information and respiratory samples were collected at enrollment. Respiratory viruses were detected with multiplex PCR and influenza specific RT-PCR assays. Participants were followed-up 14 and 28 days after inclusion. Severity of disease as measured by hospitalization with acute respiratory infections was compared between single and dual viral infections. Results Among 5,662 participants in the study, either one (n=3,285) or two (n=641) viruses were detected in 3,926 participants. Rhinovirus (n=1,433), influenza (n=888), and coronaviruses (n=703) were the most frequently detected viruses (either alone or in co-infection). Bocavirus, respiratory syncytial virus (RSV), metapneumovirus, and rhinovirus cases were hospitalized more often than other viruses. Bocavirus+rhinovirus cases were hospitalized more often than those with rhinovirus alone (but not bocavirus alone). RSV cases were more likely to be hospitalized than cases with co-infections of RSV and parainfluenza virus or coronavirus. Metapneumovirus cases were hospitalized more often than those co-infected with metapneumovirus+coronavirus. Conclusions In this study, detection of two viruses did not significantly increase hospitalizations compared with single virus infections. Larger studies will allow for distinguishing between sequential and simultaneous infection as well as for a better understanding of the role of each virus during the evolution of acute respiratory episodes.

1998 ◽  
Vol 9 (2) ◽  
pp. 93-107 ◽  
Author(s):  
Shiro Shigeta

The causative agents of acute respiratory infections (ARI) in infants and children are mostly thought to be viruses. Some ARI in adult patients may be caused by bacteria but most often the causes are virus infections. When ARI affect immunocompromised patients or the elderly the mortality rates are significantly higher than in immunocompetent individuals. Many types of viruses cause ARI. Among them, influenza viruses A and B and respiratory syncytial virus (RSV) are thought to be the most important because of the severity of illness after infection and their high communicability in the human population. Recently, several novel antiviral drugs against ARI have been developed and some are proceeding in clinical trials. This review covers current investigations into antiviral compounds targeted at several points in the virus life-cycle. This includes PM-523, which broadly inhibits ortho- and paramyxoviruses, two neuraminidase inhibitors for influenza virus, neutralizing antibody to RSV and chimeric soluble ICAM-1–IgA molecules targeted against rhinoviruses.


Author(s):  
Fahimeh Sadat Aghamirmohammadali ◽  
Kaveh Sadeghi ◽  
Nazanin Zahra Shafiei-Jandaghi ◽  
Zahra Khoban ◽  
Talat Mokhtari-Azad ◽  
...  

Background and Objectives: Severe acute respiratory infections (SARI) remain an important cause for childhood morbid- ity worldwide. We designed a research with the objective of finding the frequency of respiratory viruses, particularly WU and KI polyomaviruses (WUPyV & KIPyV), human coronaviruses (HCoVs), human respiratory syncytial virus (HRSV) and human parechovirus (HPeV) in hospitalized children who were influenza negative. Materials and Methods: Throat swabs were collected from children younger than 5 years who have been hospitalized for SARI and screened for WUPyV, KIPyV, HCoVs, HRSV and HPeV using Real time PCR. Results: A viral pathogen was identified in 23 (11.16%) of 206 hospitalized children with SARI. The rate of virus detection was considerably greater in infants <12 months (78.2%) than in older children (21.8%). The most frequently detected vi- ruses were HCoVs with 7.76% of positive cases followed by KIPyV (2%) and WUPyV (1.5%). No HPeV and HRSV were detected in this study. Conclusion: This research shown respiratory viruses as causes of childhood acute respiratory infections, while as most of mentioned viruses usually causes mild respiratory diseases, their frequency might be higher in outpatient children. Mean- while as HRSV is really sensitive to inactivation due to environmental situations and its genome maybe degraded, then for future studies, we need to use fresh samples for HRSV detection. These findings addressed a need for more studies on viral respiratory tract infections to help public health.


2021 ◽  
Vol 5 (11) ◽  
pp. 721-727
Author(s):  
D.V. Usenko ◽  
◽  
N.Kh. Tkhakushinova ◽  
T.T. Shaturina ◽  
L.A. Ledenko ◽  
...  

This paper discusses the spread of the most common causative agents for respiratory viral infections, i.e., respiratory syncytial virus (RSV) and influenza virus (IV), during seasonal peaks and under the COVID-19 pandemic. The COVID-19 pandemic and epidemic control measures reduced the transmission of some respiratory viral pathogens. The authors specify the risks of changes in RSV epidemiology associated with restrictions and their lifting. Possible scenarios of virus "behavior" in 2021–2022 are represented. These scenarios include the return of variants registered at the end of 2019 and the risk of the emergence of a novel strain of zoonotic flu that may result in a novel viral pandemic. It was demonstrated that effective monitoring of causative agent circulation, timely specific prophylaxis (particularly in high-risk groups), and early effective antiviral therapy are crucial irrespective of the possible scenario of respiratory viral infection. Modern principles of complex flu and acute respiratory viral infection treatment using an antiviral agent based on rimantadine and sodium alginate are addressed. KEYWORDS: flu, COVID-19, pandemic, respiratory syncytial infection, children, treatment, rimantadine, sodium alginate. FOR CITATION: Usenko D.V., Tkhakushinova N.Kh., Shaturina T.T. et al. Acute respiratory infections and flu during the COVID-19 pandemic. What to expect in 2021–2022? Russian Medical Inquiry. 2021;5(11):721–727 (in Russ.). DOI: 10.32364/2587-6821-2021- 5-11-721-727.


2019 ◽  
Vol 50 (3) ◽  
pp. 159-166 ◽  
Author(s):  
Jan Styczyński

AbstractViruses are a form of life that possess genes but do not have a cellular structure. Viruses do not have their own metabolism, and they require a host cell to make new products; therefore, they cannot naturally reproduce outside a host cell. The objective of this paper is to present the basic practical clinical roles of viruses in patients with hematological diseases including malignancies and non-malignan- cies, as well as those undergoing hematopoietic cell transplantation (HCT), with the focus on herpesviruses causing latent infections in severely immunocompromised patients. From the hematologist point of view, viruses can play a major role in four conditions: causing infections; causing lymphoproliferations and/or malignancies; causing (pan)cytopenia; and used as vectors in treatment (e.g., gene therapy, CAR-T cells). Taking into account the role of viruses in hematology, infection is the most frequent condition. Among DNA viruses, the highest morbidity potential for human is expressed by Herpesviridiae (herpesviruses), Adenoviridae (adenovirus; ADV), Polyomavirus (BKV, JCV), and Bocavirus. RNA viruses can play a role in pathogenesis of different clinical conditions and diseases: lymphoproliferative disorders and malignancy, possibly causing NHL, AML, MDS, and others (HCV, HIV, and others); pancytopenia and aplastic anemia (HIV, HCV, Dengue virus); respiratory infections (community-acquired respiratory virus infections; CARV) caused by Orthomyxoviruses (e.g. influenza A/B), Paramyxoviruses (e.g. human parainfluenza virus PIV-1, -2, -3, and -4; respiratory syncytial virus RSV-A and -B), picornaviruses (e.g., human rhinovirus), coronaviruses (e.g., human coronavirus), Pneumoviridiae (e.g., human metapneumovirus), and potentially other viruses.


Author(s):  
С.В. Николаева ◽  
Д.В. Усенко ◽  
Ю.Н. Хлыповка ◽  
А.В. Горелов

Вирусные инфекции дыхательных путей являются наиболее частой причиной инфекционных заболеваний, особенно у детей. В большинстве случаев, особенно при поражении верхних дыхательных путей, острые респираторные вирусные инфекции протекают в легкой или среднетяжелой форме и часто купируются самостоятельно. Фармакологические средства для лечения или профилактики данных инфекций у детей в настоящее время ограничены. Многочисленные исследования доказали эффективность пробиотиков в лечении и профилактике заболеваний желудочно-кишечного тракта, таких как инфекционные и антибиотик-ассоциированные диареи, диареи путешественников, некротизирующий энтероколит, инфекция Helicobacter pylori, а также атопических заболеваний. Становится актуальным изучение эффективности пробиотиков в качестве средств профилактики острых респираторных инфекций среди детей и взрослых. Данные in vitro демонстрируют, что пробиотики обладают штаммоспецифическим иммуномодулирующим действием на иммунные клетки. Показано, что пробиотики эффективны в подавлении репликации различных респираторных вирусов, включая вирусы гриппа и респираторно-синцитиальный вирус. Подобные эффекты были продемонстрированы на мышах, было показано, что пробиотики способны снижать титры вируса в тканях легких и модулировать экспрессию противовирусных и провоспалительных генов до и после вирусной инфекции. Доклинические исследования также показывают уменьшение симптомов заболевания у мышей, что указывает на потенциальную клиническую пользу. Данные литературы по изучению применения пробиотиков и синбиотиков при вирусных инфекциях респираторного тракта показывают, что их использование связано с более низкой частотой и меньшей продолжительностью легких форм респираторной инфекции как у детей, так и у взрослых. Целесообразно дальнейшее проведение исследований для получения адекватных выводов об эффективности пробиотиков и синбиотиков при острых респираторных инфекциях. Viral infections of the respiratory tract are the most common cause of infectious diseases, especially in children. In most cases, especially when the upper respiratory tract is affected, acute respiratory viral infections are mild to moderate and often stop spontaneously. Pharmacological agents for the treatment or prevention of these infections in children are currently limited. Numerous studies have proven the effectiveness of probiotics in the treatment and prevention of diseases of the gastrointestinal tract, such as infectious and antibiotic-associated diarrhea, traveler's diarrhea, necrotizing enterocolitis, Helicobacter pylori infection, as well as atopic diseases. It is becoming urgent to study the effectiveness of probiotics as prophylactic agents for acute respiratory infections. among children and adults. In vitro data demonstrate that probiotics have strain-specific immunomodulatory effects on immune cells. Probiotics have been shown to be effective in suppressing the replication of various respiratory viruses, including influenza viruses and respiratory syncytial virus. Similar effects have been demonstrated in mice with the ability of probiotics to reduce viral titers in lung tissues and modulate the expression of antiviral and pro-inflammatory genes before and after viral infection. Preclinical studies also show improvement in symptoms in mice, indicating potential clinical benefit. Literature data on the use of probiotics and synbiotics for viral infections of the respiratory tract show that their use is associated with a lower frequency and duration of mild forms of respiratory infection in both children and adults. It is advisable to further conduct research necessary to obtain adequate conclusions about the effectiveness of probiotics and synbiotics in acute respiratory infections.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Juan C. Muñoz-Escalante ◽  
Andreu Comas-García ◽  
Sofía Bernal-Silva ◽  
Daniel E. Noyola

AbstractRespiratory syncytial virus (RSV) is a major cause of respiratory infections and is classified in two main groups, RSV-A and RSV-B, with multiple genotypes within each of them. For RSV-B, more than 30 genotypes have been described, without consensus on their definition. The lack of genotype assignation criteria has a direct impact on viral evolution understanding, development of viral detection methods as well as vaccines design. Here we analyzed the totality of complete RSV-B G gene ectodomain sequences published in GenBank until September 2018 (n = 2190) including 478 complete genome sequences using maximum likelihood and Bayesian phylogenetic analyses, as well as intergenotypic and intragenotypic distance matrices, in order to generate a systematic genotype assignation. Individual RSV-B genes were also assessed using maximum likelihood phylogenetic analyses and multiple sequence alignments were used to identify molecular markers associated to specific genotypes. Analyses of the complete G gene ectodomain region, sequences clustering patterns, and the presence of molecular markers of each individual gene indicate that the 37 previously described genotypes can be classified into fifteen distinct genotypes: BA, BA-C, BA-CC, CB1-THB, GB1-GB4, GB6, JAB1-NZB2, SAB1, SAB2, SAB4, URU2 and a novel early circulating genotype characterized in the present study and designated GB0.


2021 ◽  
Vol 13 (3) ◽  
pp. 363-382
Author(s):  
Mario Dioguardi ◽  
Angela Pia Cazzolla ◽  
Claudia Arena ◽  
Diego Sovereto ◽  
Giorgia Apollonia Caloro ◽  
...  

COVID-19 (Coronavirus Disease 2019) is an emerging viral disease caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which leads to severe respiratory infections in humans. The first reports came in December 2019 from the city of Wuhan in the province of Hubei in China. It was immediately clear that children developed a milder disease than adults. The reasons for the milder course of the disease were attributed to several factors: innate immunity, difference in ACE2 (angiotensin-converting enzyme II) receptor expression, and previous infections with other common coronaviruses (CovH). This literature review aims to summarize aspects of innate immunity by focusing on the role of ACE2 expression and viral infections in children in modulating the antibody response to SARS-CoV-2 infection. This review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles deemed potentially eligible were considered, including those dealing with COVID-19 in children and providing more up-to-date and significant data in terms of epidemiology, prognosis, course, and symptoms, focusing on the etiopathogenesis of SARS-CoV-2 disease in children. The bibliographic search was conducted using the search engines PubMed and Scopus. The following search terms were entered in PubMed and Scopus: COVID-19 AND ACE2 AND Children; COVID-19 AND Immunity innate AND children. The search identified 857 records, and 18 studies were applicable based on inclusion and exclusion criteria that addressed the issues of COVID-19 concerning the role of ACE2 expression in children. The scientific literature agrees that children develop milder COVID-19 disease than adults. Milder symptomatology could be attributed to innate immunity or previous CovH virus infections, while it is not yet fully understood how the differential expression of ACE2 in children could contribute to milder disease.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Zhong-Jie Li ◽  
Hai-Yang Zhang ◽  
Li-Li Ren ◽  
Qing-Bin Lu ◽  
Xiang Ren ◽  
...  

AbstractNationwide prospective surveillance of all-age patients with acute respiratory infections was conducted in China between 2009‒2019. Here we report the etiological and epidemiological features of the 231,107 eligible patients enrolled in this analysis. Children <5 years old and school-age children have the highest viral positivity rate (46.9%) and bacterial positivity rate (30.9%). Influenza virus, respiratory syncytial virus and human rhinovirus are the three leading viral pathogens with proportions of 28.5%, 16.8% and 16.7%, and Streptococcus pneumoniae, Mycoplasma pneumoniae and Klebsiella pneumoniae are the three leading bacterial pathogens (29.9%, 18.6% and 15.8%). Negative interactions between viruses and positive interactions between viral and bacterial pathogens are common. A Join-Point analysis reveals the age-specific positivity rate and how this varied for individual pathogens. These data indicate that differential priorities for diagnosis, prevention and control should be highlighted in terms of acute respiratory tract infection patients’ demography, geographic locations and season of illness in China.


2021 ◽  
Vol 9 (7) ◽  
pp. 1519
Author(s):  
Sonia R. Isaacs ◽  
Dylan B. Foskett ◽  
Anna J. Maxwell ◽  
Emily J. Ward ◽  
Clare L. Faulkner ◽  
...  

For over a century, viruses have left a long trail of evidence implicating them as frequent suspects in the development of type 1 diabetes. Through vigorous interrogation of viral infections in individuals with islet autoimmunity and type 1 diabetes using serological and molecular virus detection methods, as well as mechanistic studies of virus-infected human pancreatic β-cells, the prime suspects have been narrowed down to predominantly human enteroviruses. Here, we provide a comprehensive overview of evidence supporting the hypothesised role of enteroviruses in the development of islet autoimmunity and type 1 diabetes. We also discuss concerns over the historical focus and investigation bias toward enteroviruses and summarise current unbiased efforts aimed at characterising the complete population of viruses (the “virome”) contributing early in life to the development of islet autoimmunity and type 1 diabetes. Finally, we review the range of vaccine and antiviral drug candidates currently being evaluated in clinical trials for the prevention and potential treatment of type 1 diabetes.


Sign in / Sign up

Export Citation Format

Share Document